Effect of Small Interference RNA Targeting HIF-1α Mediated by rAAV Combined l-Ascorbate on Pancreatic Tumors in Athymic Mice

被引:20
作者
Chen, Chuangui [1 ,2 ]
Sun, Jinjin [1 ]
Liu, Geng [1 ]
Chen, Jianqiu [1 ]
机构
[1] TianJin Med Univ, Hosp 2, Dept Surg, Tianjin 300211, Peoples R China
[2] Karolinska Univ Hosp, Dept Surg, S-14186 Stockholm, Sweden
关键词
Recombinant adeno-associated virus (rAAV); Hypoxia inducible factor (HIF); Small interference RNA (siRNA); L-Ascorbate; HYPOXIA-INDUCIBLE FACTOR; CANCER; ANGIOGENESIS; GROWTH; HIF-1; METASTASIS; 1-ALPHA;
D O I
10.1007/s12253-008-9063-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To study the effect of recombinant adeno-associated virus (rAAV) vector bearing small inference RNA (siRNA) targeting hypoxia inducible factor 1 alpha (HIF-1 alpha) combined l-ascorbate on pancreatic tumors in athymic mice primarily. A cassette encoding siRNA targeting HIF-1 alpha mediated by rAAV was constructed, giving rAAV-siHIF. In vitro, rAAV-hrGFP, rAAV-siHIF and l-ascorbate which were used alone or in combination were delivered to exponentially growing MiaPaCa2 cells. Then, we examined the expression of HIF-1 alpha mRNA and protein, the secretion of VEGF in MiaPaCa2 cells under hypoxic condition with Real-time PCR, Western Blot, ELISA, respectively. In vivo, MiaPaCa2 cells were inoculated subcutaneously on the back of nude mice. Nude mice with xenograft tumor were randomly divided into equal groups and were injected with rAAV-hrGFP or rAAV-siHIF or were fed with l-ascorbate. Then, we measured the size of tumor every 3 days and drew a tumor growth curve. After 30 days, all mice were sacrificed and the tumors were dissected. At last, we examined the expression of HIF-1 alpha, VEGF and CD34 by immunohistochemistry and counted micro-vessel density (MVD). In vitro, we found that rAAV-siHIF could inhibit the expression of HIF-1 alpha mRNA and protein in MiaPaCa2 human pancreatic cancer cells but l-ascorbate could only restrain the expression of HIF-1 alpha protein. Moreover, rAAV-siHIF and l-ascorbate could all inhibit the secretion of vascular VEGF. In vivo, we found that rAAV-siHIF could inhibit the growth of nude mice xenograft tumor and the expression of HIF-1 alpha and VEGF and MVD while -ascorbate can only inhibit the growth of xenograft tumor in the early and middle stage. These results suggest that rAAV-siHIF and l-ascorbate can inhibit the growth of nude mice xenograft tumor and HIF-1 alpha could be a target of pancreatic cancer genetic and pharmacological therapy.
引用
收藏
页码:109 / 114
页数:6
相关论文
共 24 条
[1]   Tumoral angiogenesis:: physiopathology, prognostic value and therapeutical prospects [J].
André, T ;
Chastre, E ;
Kotelevets, L ;
Vaillant, JC ;
Louvet, C ;
Balosso, J ;
Le Gall, E ;
Prévot, S ;
Gespach, C .
REVUE DE MEDECINE INTERNE, 1998, 19 (12) :904-913
[2]  
Brizel DM, 1996, CANCER RES, V56, P941
[3]   Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer [J].
Büchler, P ;
Reber, HA ;
Büchler, M ;
Shrinkante, S ;
Büchler, MW ;
Friess, H ;
Semenza, GL ;
Hines, OJ .
PANCREAS, 2003, 26 (01) :56-64
[4]   Role of angiogenesis in tumor growth and metastasis [J].
Folkman, J .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :15-18
[5]  
Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
[6]  
Frelin C, 2000, ANN ENDOCRINOL-PARIS, V61, P70
[7]  
Knowles HJ, 2003, CANCER RES, V63, P1764
[8]   Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis [J].
Lu, HS ;
Forbes, RA ;
Verma, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (26) :23111-23115
[9]   Independent function of two destruction domains in hypoxia-inducible factor-α chains activated by prolyl hydroxylation [J].
Masson, N ;
Willam, C ;
Maxwell, PH ;
Pugh, CW ;
Ratcliffe, PJ .
EMBO JOURNAL, 2001, 20 (18) :5197-5206
[10]   HIF-1:: master and commander of the hypoxic world -: A pharmacological approach to its regulation by siRNAs [J].
Mazure, NM ;
Brahimi-Horn, MC ;
Berta, MA ;
Benizri, E ;
Bilton, RL ;
Dayan, F ;
Ginouvès, A ;
Berra, E ;
Pouysségur, J .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (06) :971-980